Navigating Forward-Looking Statements and Risks in AIM ImmunoTech's Interview| Thomas Equels, CEO, AIM ImmunoTech Inc. 00:10:00
The interview presents forward-looking statements accompanied by disclaimers regarding potential risks and uncertainties involved, particularly in the context of AIM ImmunoTech's Pancreatic Cancer Program with Ampligen, highlighting the need for further testing and trials to determine efficacy, while also acknowledging the broader landscape of COVID-19 treatment research.